Evidence map›Paper›PMID 38283151›Full record

ArticleFrontiers in genetics2023

Selective screening for inborn errors of metabolism using tandem mass spectrometry in West Kazakhstan children: study protocol.

Gulmira Zharmakhanova, Victoria Kononets, Saule Balmagambetova, Lyazzat Syrlybayeva, Eleonora Nurbaulina, Zhanna Zhussupova, Svetlana Sakhanova, Dinmukhamed Ayaganov, Svetlana Kim, Akmaral Zhumalina

Registry-linked trialAbstract read
In one paragraph

Article in Frontiers in genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05910151 (Introduction of Tandem Mass Spectrometry), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05910151 unknown statusnot on this map

Introduction of Tandem Mass Spectrometry (MS/MS) Technology in the Program of Selective Screening of Hereditary Metabolic Diseases in Kazakhstan

Typeobservational_patient_registrySponsorWest Kazakhstan Medical UniversityRan2022 to 2024Enrolled2,250ConditionsPropionic/Methylmalonic Acidemias, Maple Syrup Urine Disease, Citrullinemia, Argininosuccinic AciduriaArmsObtaining Dry Blood Spots From Healthy Newborns (Aged 1-7 Days), Obtaining Dry Blood Spots From Healthy Children Aged 8 Days - 7 Years, Obtaining Dry Blood Spots From Healthy Children Aged 8-18 Years, Obtaining Dry Blood Spots From High-risk Newborns (Aged 1-7 Days), Obtaining Dry Blood Spots From High-risk childrens (Aged 8 Days- 7 years)
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gulmira ZharmakhanovaDepartment of Natural Sciences, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan.
Victoria KononetsDepartment of Natural Sciences, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan.
Saule BalmagambetovaDepartment of Oncology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan.
Lyazzat SyrlybayevaDepartment of Natural Sciences, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan.
Eleonora NurbaulinaDepartment of General Medical Practice, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan.
Zhanna ZhussupovaAktobe Regional Tertiary Care Center, Department of Neonatal Pathology, Aktobe, Kazakhstan.
Svetlana SakhanovaScientific-Practical Center, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan.
Dinmukhamed AyaganovDepartment of Neurology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan.
Svetlana KimDepartment of Children's Diseases No. 2, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan.
Akmaral ZhumalinaDepartment of Children's Diseases No. 1 with Neonatology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Data on the prevalence of most inborn errors of metabolism are still unavailable in Kazakhstan. The study aims to perform selective screening for hereditary metabolic diseases among patients aged from 1 day to 18 years in western Kazakhstan using the LC-MS/MS method, with establishing the reference values for the content of amino acids, acylcarnitines, and succinylacetone in blood samples of healthy children. Tasks: 1. To assess the burden of metabolic disorders detected by LC-MS/MS in western Kazakhstan by examination of children at clinical risk in pediatric clinics throughout the region; https://www.frontiersin.org/register?returnUrl=https://loop.frontiersin.org 2. To set the reference values of metabolites in the child population; 3. To analyze the age distribution, prevalence, and age of onset for each identified IEM, further comparing the obtained findings with those from previously published reports in other populations.

methodsTo set the reference values of 51 metabolites in the child population, 750 healthy children will be included. The selective screening will be performed among 1,500 patients aged 1 day to 18 years with suspected hereditary metabolic disorders. ANTICIPATED

resultsThe results of selective screening will be interpreted by comparison with the reference values established. Diagnosis will be based on clinical signs, blood levels of amino acids, acylcarnitines, succinylacetone, and urine levels of organic acids and tests for gene mutations. An assessment of 37 inborn errors of metabolism frequencies in high-risk children will be performed. The research will further develop the national as selective as expanded newborn screening programs. The study was registered in clinicaltrials. gov (https://www. CLINICALTRIALS: gov/study/NCT05910151) on 16 June 2023.

Indexed as

acylcarnitinesamino acidsinborn errors of metabolismKazakhstanselective screeningsuccinylacetonetandem mass spectrometry

Identifiers

PMID38283151
PMCPMC10811460

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.